This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Grandis, J. R. Articles by Morel, P. A. Search for Related Content PubMed PubMed Citation Articles by Grandis, J. R. Articles by Morel, P. A.

Human Leukocyte Antigen Class I Allelic and Haplotype Loss in Squamous Cell Carcinoma of the Head and Neck: Clinical and Immunogenetic Consequences

Departments of Otolaryngology and Pharmacology [J. R. G., S. D. D.], Medicine [D. M. F., P. A. M.], and Pathology [M. F. M.], University of Pittsburgh and the University of Pittsburgh Cancer Institute [J. R. G., P. A. M., W. E. G.], Pittsburgh, Pennsylvania 15213

The expression of human leukocyte antigen (HLA) class I molecules on the cell surface is necessary for the presentation of peptide antigens to cytotoxic CD8+ T lymphocytes of the immune system. Down-regulation of HLA class I gene expression has been implicated in tumorigenesis, including squamous cell carcinoma of the head and neck (SCCHN). Loss of MHC class I antigens may be one mechanism by which tumor cells escape immune detection. We performed prospective immunostaining of 26 primary SCCHN tumors and samples of normal mucosa harvested several centimeters away from the primary tumor, using a large panel of antibodies directed against allele-specific as well as monomorphic determinants of HLA class I molecules. Loss of expression of HLA class I proteins in the tumor was found in 50% (13 of 26) of primary tumors and was highly correlated with HLA loss in the corresponding normal mucosa (P < 0.0001). Further analysis demonstrated that the loss of HLA class I expression in the tumor was significantly associated with regional lymph node metastases (nodal stage; P = 0.0388), and that the number of HLA class I alleles lost in the normal mucosa was associated with subsequent development of a new primary aerodigestive tract cancer (P = 0.042). A patient with two metachronous cancers available for analysis had no evidence of HLA loss in the first tumor, demonstrated allelic loss in the second cancer, and subsequently died of disease. These results suggest that the loss of expression of HLA class I alleles may have prognostic implications.

This article has been cited by other articles:

				K. W. Hance, C. J. Rogers, D. A. Zaharoff, D. Canter, J. Schlom, and J. W. Greiner The Antitumor and Immunoadjuvant Effects of IFN-{alpha} in Combination with Recombinant Poxvirus Vaccines Clin. Cancer Res., April 1, 2009; 15(7): 2387 - 2396. [Abstract] [Full Text] [PDF]

				T. So, M. Takenoyama, M. Mizukami, Y. Ichiki, M. Sugaya, T. Hanagiri, K. Sugio, and K. Yasumoto Haplotype Loss of HLA Class I Antigen as an Escape Mechanism from Immune Attack in Lung Cancer Cancer Res., July 1, 2005; 65(13): 5945 - 5952. [Abstract] [Full Text] [PDF]

				M. Meissner, T. E. Reichert, M. Kunkel, W. Gooding, T. L. Whiteside, S. Ferrone, and B. Seliger Defects in the Human Leukocyte Antigen Class I Antigen Processing Machinery in Head and Neck Squamous Cell Carcinoma: Association with Clinical Outcome Clin. Cancer Res., April 1, 2005; 11(7): 2552 - 2560. [Abstract] [Full Text] [PDF]

				E. Ryschich, T. Notzel, U. Hinz, F. Autschbach, J. Ferguson, I. Simon, J. Weitz, B. Frohlich, E. Klar, M. W. Buchler, et al. Control of T-Cell-Mediated Immune Response by HLA Class I in Human Pancreatic Carcinoma Clin. Cancer Res., January 15, 2005; 11(2): 498 - 504. [Abstract] [Full Text] [PDF]

				M. Vitale, G. Pelusi, B. Taroni, G. Gobbi, C. Micheloni, R. Rezzani, F. Donato, X. Wang, and S. Ferrone HLA Class I Antigen Down-Regulation in Primary Ovary Carcinoma Lesions: Association with Disease Stage Clin. Cancer Res., January 1, 2005; 11(1): 67 - 72. [Abstract] [Full Text] [PDF]

				T. Matsubara, K. Yamada, and A. Nakagawa Risk of Second Primary Malignancy After Esophagectomy for Squamous Cell Carcinoma of the Thoracic Esophagus J. Clin. Oncol., December 1, 2003; 21(23): 4336 - 4341. [Abstract] [Full Text] [PDF]

				M. Sugaya, M. Takenoyama, T. Osaki, M. Yasuda, A. Nagashima, K. Sugio, and K. Yasumoto Establishment of 15 Cancer Cell Lines From Patients With Lung Cancer and the Potential Tools for Immunotherapy* Chest, July 1, 2002; 122(1): 282 - 288. [Abstract] [Full Text] [PDF]